Primary Liver Cancer
Conditions
Brief summary
Through follow-up testing of patients with primary liver cancer who underwent hepatectomy, liver transplantation, ablation therapy, or transarterial chemoembolization (TACE), a blinded comparative trial was conducted at each monitoring site. This trial evaluated the combined methylation detection kit for GNB4 and Riplet genes (fluorescent PCR method) against the clinical reference standard (defined as the physician's comprehensive diagnosis based on clinical guidelines and other criteria). The study evaluated the clinical performance of the assay in diagnosing primary liver cancer recurrence and validated the clinical efficacy of methylation detection kits for monitoring recurrence after primary liver cancer treatment.
Interventions
DIAGNOSTIC_TESTplasma GNB4 and Riplet genes methylation detection
Liver cancer patients undergo methylation testing at different follow-up time points after treatment
Sponsors
Wuhan Ammunition Life-tech Co., Ltd
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Primary liver cancer
Exclusion criteria
* Concurrent other malignant tumors; * Ineligible for hepatectomy, liver transplantation, ablation, or TACE therapy; * Negative methylation status prior to treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| sensitivity | Through study completion, an average of 1 year |
| specificity | Through study completion, an average of 1 year |
Countries
China
Contacts
CONTACTTingting Li, phD
Outcome results
None listed